Day 1 - Industry Summit - 10 February

Expand All
08:20
08:40
08:50
Andrew Patterson Business Commentator
09:05
Dr Zahra Champion Executive Director, BioTechNZ
09:10

Meet and greet your fellow attendees in random breakout rooms in this icebreaker session.

09:20
  • Looking into how cannabinoids are being used across sector i.e. cosmetics, beverages and more
  • Insights into evidence on consumption trends across the globe
    • What impact is medicinal cannabis having?
  • How is this driving product design in the industry?

Melissa Clark-Reynolds Futurist, futurecentre.nz
09:50
Hon. Andrew Little Minister of Health, Labour Party
10:05
  • Comparing New Zealand’s medicinal cannabis industry to the world
  • The opportunity to join the global industry and be amongst the global players
  • What is unique about New Zealand’s harvest (and product) to drive a global opportunity to drive our economy as well as contribute to global healthcare and wellbeing outcomes?
  • What are the milestones that the industry needs to reach to achieve a commercially sustainable industry?
  • Keeping it local – what are the collaboration options for Maori businesses and organisations to expand their interest in primary industries?

Manu Caddie, Co-Founder, Kaihautu – Innovation and Regulation, Rua Bioscience

Carmen Doran Chief Executive Officer, Helius Therapeutics
Mark Lucas Chief Executive Officer, Cannasouth
Tim Aldridge Managing Director, Puro
Mitch Cuevas Pharmaceutical Director, Eqalis
11:00
11:15
Industry
Andrew Patterson Business Commentator
11:20
Industry
Carmen Doran Chief Executive Officer, Helius Therapeutics
Eva Neshat Founder and Chief Executive Officer, Elysian Pharmaceuticals & CannaPlus+
Zoë Reece Founder and CEO, Ora Pharm
Dr Dottie Clower Chief Scientific Officer, Puro
12:20
Industry

• Types of investment
• Trends
• Future of investments

Kristen Lunman Co-Founder and GM, Hatch
12:50
Industry

This presentation will highlight the commercial potential for medicinal cannabis or hemp beyond its primary use by taking a ‘whole of resource’ approach. It will outline how the Bioresource Processing Alliance and research providers can help industry partners identify high-value opportunities from low-value biological resources.

Andrew Cameron Principal Consultant, Callaghan Innovation
Anna Yallop General Manager, Bioresource Processing Alliance
13:20
13:40
14:10
  • Medicinal cannabis licensing regime
  • Verification of products against the minimum quality standards
  • Regulation changes
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
14:40
  • Providing an overview of AUS/NZ approach to growing cannabis for medicinal purposes
    • An in-depth discussion on indoor versus outdoor growth – how do they differ and will one dominate over the other?
  • Showcasing technology in play to capture data and assisting with cultivation
  • The road that lays ahead – opportunities for growth and collaboration
Tom Forrest Cultivation Director, Puro
15:20
08:20
08:40
08:50
Andrew Patterson Business Commentator
09:05
Dr Zahra Champion Executive Director, BioTechNZ
09:10

Meet and greet your fellow attendees in random breakout rooms in this icebreaker session.

09:20
  • Looking into how cannabinoids are being used across sector i.e. cosmetics, beverages and more
  • Insights into evidence on consumption trends across the globe
    • What impact is medicinal cannabis having?
  • How is this driving product design in the industry?

Melissa Clark-Reynolds Futurist, futurecentre.nz
09:50
Hon. Andrew Little Minister of Health, Labour Party
10:05
  • Comparing New Zealand’s medicinal cannabis industry to the world
  • The opportunity to join the global industry and be amongst the global players
  • What is unique about New Zealand’s harvest (and product) to drive a global opportunity to drive our economy as well as contribute to global healthcare and wellbeing outcomes?
  • What are the milestones that the industry needs to reach to achieve a commercially sustainable industry?
  • Keeping it local – what are the collaboration options for Maori businesses and organisations to expand their interest in primary industries?

Manu Caddie, Co-Founder, Kaihautu – Innovation and Regulation, Rua Bioscience

Carmen Doran Chief Executive Officer, Helius Therapeutics
Mark Lucas Chief Executive Officer, Cannasouth
Tim Aldridge Managing Director, Puro
Mitch Cuevas Pharmaceutical Director, Eqalis
11:00
11:15
Science
Imche Fourie Co-Founder & CEO, Outset Ventures
11:20
Science

• New Zealand gene bank
• different genetic technologies
• development of unique plants to those grown internationally
• Which traits to select- from disease resistance to cannabinoid profiles
• role of data management in a well-run breeding programme

Dr Anna Campbell Consultant, AbacusBio
11:50
Science
Kai Keli'iho'omalu Cultivation Manager, Helius Therapeutics
12:20
Science
Carmen Doran Chief Executive Officer, Helius Therapeutics
Ali Seyfoddin Associate Professor of Drug Delivery and Biological Engineering Deputy Head of School, School of Science, Auckland University of Technology
12:50
Science
Dr. Adele Hosseini, PhD Chief Scientific Officer, Bod Australia
13:20
13:40
14:10
  • Medicinal cannabis licensing regime
  • Verification of products against the minimum quality standards
  • Regulation changes
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
14:40
  • Providing an overview of AUS/NZ approach to growing cannabis for medicinal purposes
    • An in-depth discussion on indoor versus outdoor growth – how do they differ and will one dominate over the other?
  • Showcasing technology in play to capture data and assisting with cultivation
  • The road that lays ahead – opportunities for growth and collaboration
Tom Forrest Cultivation Director, Puro
15:20